The
ophthalmology drugs market covers drugs that are used in the treatment of eye
related diseases such as refractive errors, cataracts, glaucoma,
conjunctivitis, retinal diseases, and macular degeneration. Some of the major
ophthalmic drugs include Eylea, Lucentis, Restasis, Vigamox, Azopt, and
Lotemax.
Read
More:
The substantial growth of the market
from $27 billion in 2017 to $37 billion by 2021 is due to
the expected rise in prevalence of eye conditions such as age-related macular
degeneration (AMD), diabetic retinopathy and glaucoma that require
ophthalmology drugs.
In the report, the global ophthalmology drugs
market is divided into three segments. Other ophthalmology drugs occupy the
major share in the market, accounting for nearly three-fifth of the market and
the remaining segments, antiglaucoma drugs and dry eye medication occupy
two-fifth of the market share.
Sample Report:
The USA was the largest country in the ophthalmology drugs
market in 2017, accounting for more than one-fourth of the market share. This
can be attributed to the high per capita healthcare expenditure and increasing
geriatric population in the country. Germany and Japan followed
the USA as the next largest countries in the market.
The ophthalmology drugs market is fragmented
with a number of large and small organizations. The top
five competitors in the market made up around 65% of the total market in 2017.
Novartis AG was the largest competitor of the market, followed by F.
Hoffmann-La Roche Ltd., Allergan Plc, Valeant Pharmaceuticals Intl Inc. and
Bayer AG. Novartis is a multinational pharmaceutical company that develops,
manufacture and markets healthcare products. The company was founded in 1970
and is headquartered in Basel, Switzerland.
About
The Business Research Company.
The Business Research Company is a
Business Intelligence Company which excels in company, market and consumer
research. It has
offices in the UK, the US and India and a network of trained researchers in 15
countries globally.
Contact Information.
The Business Research Company
Europe:
+44 207 1930 708
Asia: +91
8897263534
Americas:
+1 315 623 0293
No comments:
Post a Comment